Terms: = Lung cancer AND LDH AND Staging
47 results:
1. Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients.
Kloker LD; Sidiras M; Flaadt T; Brecht IB; Deinzer CKW; Groß T; Benzler K; Zender L; Lauer UM
Lung Cancer; 2024 Mar; 189():107496. PubMed ID: 38301600
[TBL] [Abstract] [Full Text] [Related]
2. Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Richtig E; Nguyen VA; Koelblinger P; Wolf I; Kehrer H; Saxinger W; Ressler JM; Weinlich G; Meyersburg D; Hafner C; Jecel-Grill E; Kofler J; Lange-Asschenfeldt B; Weihsengruber F; Rappersberger K; Svastics N; Gasser K; Seeber A; Kratochvill F; Nagler S; Mraz B; Hoeller C
Melanoma Res; 2024 Apr; 34(2):142-151. PubMed ID: 38092013
[TBL] [Abstract] [Full Text] [Related]
3. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
[TBL] [Abstract] [Full Text] [Related]
4. Patterns of Relapse in Small Cell lung cancer: Competing Risks of Thoracic versus CNS Relapse.
Ellis PM; Swaminath A; Pond GR
Curr Oncol; 2021 Jul; 28(4):2778-2788. PubMed ID: 34287307
[TBL] [Abstract] [Full Text] [Related]
5. [Prognostic factor analysis of patients with unresectablelung squamous cell carcinoma].
Gao X; Li Z; Shao XY; Liu XM; Liu C; Liu YP; Qu XJ; Zhang LY
Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):569-573. PubMed ID: 34034477
[No Abstract] [Full Text] [Related]
6. Clinical and radiological characteristics of patients with pulmonary marginal zone lymphoma: A single center analysis.
Husnain M; Kuker R; Reis IM; Iyer SG; Zhao W; Chapman JR; Vega F; Lossos IS; Alderuccio JP
Cancer Med; 2020 Jul; 9(14):5051-5064. PubMed ID: 32452658
[TBL] [Abstract] [Full Text] [Related]
7. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell lung cancer (NSCLC): A Large Retrospective Multicenter Study.
Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic value of metabolic parameters on baseline 18F-FDG PET/CT in small cell lung cancer.
Araz M; Soydal C; Özkan E; Sen E; Nak D; Kucuk ON; Gönüllü U; Kir KM
Q J Nucl Med Mol Imaging; 2022 Mar; 66(1):61-66. PubMed ID: 31271268
[TBL] [Abstract] [Full Text] [Related]
9. Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?
Park HL; Yoo IR; Boo SH; Park SY; Park JK; Sung SW; Moon SW
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1021-1026. PubMed ID: 30756189
[TBL] [Abstract] [Full Text] [Related]
10. [Utility of NSE, ProGRP and ldh in Diagnosis and Treatment
in Patients with Small Cell lung cancer].
Peng Y; Wang Y; Li J; Hao X; Hu X
Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
[TBL] [Abstract] [Full Text] [Related]
11. [Prognostic factors in non-small cell lung cancer patients and prognostic importance of PET/CT SUV max value].
Erdem V; Selimoğlu Şen H; Kömek H; Tanrikulu AC; Abakay A; Sezgi C; Kaya H; Senyiğit A
Tuberk Toraks; 2012; 60(3):207-17. PubMed ID: 23030745
[TBL] [Abstract] [Full Text] [Related]
12. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.
Oh JR; Seo JH; Chong A; Min JJ; Song HC; Kim YC; Bom HS
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):925-35. PubMed ID: 22270509
[TBL] [Abstract] [Full Text] [Related]
13. A single-institution validation of the AJCC staging system for stage IV melanoma.
Neuman HB; Patel A; Ishill N; Hanlon C; Brady MS; Halpern AC; Houghton A; Coit DG
Ann Surg Oncol; 2008 Jul; 15(7):2034-41. PubMed ID: 18465172
[TBL] [Abstract] [Full Text] [Related]
14. Detecting extrathoracic metastases in patients with non-small cell lung cancer: Is routine scanning necessary?
Metintas M; Ak G; Akcayir IA; Metintas S; Erginel S; Alatas F; Yildirim H; Kurt E; Ozkan R
Lung Cancer; 2007 Oct; 58(1):59-67. PubMed ID: 17566597
[TBL] [Abstract] [Full Text] [Related]
15. [Experiences with the new American Joint Committee on cancer (AJCC) classification of cutaneous melanoma].
Eigentler TK; Radny P; Kamin A; Weide B; Caroli UM; Garbe C
J Dtsch Dermatol Ges; 2005 Aug; 3(8):592-8. PubMed ID: 16033477
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic factors in mesothelioma.
Steele JP; Klabatsa A; Fennell DA; Palläska A; Sheaff MT; Evans MT; Shamash J; Rudd RM
Lung Cancer; 2005 Jul; 49 Suppl 1():S49-52. PubMed ID: 15894403
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma.
Wang TS; Johnson TM; Cascade PN; Redman BG; Sondak VK; Schwartz JL
J Am Acad Dermatol; 2004 Sep; 51(3):399-405. PubMed ID: 15337983
[TBL] [Abstract] [Full Text] [Related]
18. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
Berghmans T; Lafitte JJ; Thiriaux J; VanHoutte P; Lecomte J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Mommen P; Ninane V; Sculier JP;
Lung Cancer; 2004 Sep; 45(3):339-48. PubMed ID: 15301874
[TBL] [Abstract] [Full Text] [Related]
19. An evidence-based staging system for cutaneous melanoma.
Balch CM; Soong SJ; Atkins MB; Buzaid AC; Cascinelli N; Coit DG; Fleming ID; Gershenwald JE; Houghton A; Kirkwood JM; McMasters KM; Mihm MF; Morton DL; Reintgen DS; Ross MI; Sober A; Thompson JA; Thompson JF
CA Cancer J Clin; 2004; 54(3):131-49; quiz 182-4. PubMed ID: 15195788
[TBL] [Abstract] [Full Text] [Related]
20. Increased CYFRA 21-1 and CEA levels are negative predictors of outcome in p-stage I NSCLC.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2003; 23(5b):4085-93. PubMed ID: 14666606
[TBL] [Abstract] [Full Text] [Related]
[Next]
